Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > November 30, 2020
Daily News
November 30, 2020
- MHLW Approves Label Expansions for Forxiga, Trelegy, Evrenzo, Cabometyx and More
November 30, 2020
- Chugai Now Takes Nissan Chemical to Court over Edirol Patent, Seeks Damages from Sawai, Nichi-Iko Too
November 30, 2020
- Ono’s Cancer Cachexia Drug to Finally Come Up for PAFSC Review on Dec. 11
November 30, 2020
- Jardiance Filed for Chronic Heart Failure in Japan: BI/Lilly
November 30, 2020
- MHLW Says 7,500 Vaccine Freezers for Storage at Minus 20 Degrees C, Presumably for Moderna Shot
November 30, 2020
- 4 Scientific Societies Call for COVID-19 Vaccine Recipient Registry
November 30, 2020
- CEFP Member Urges Off-Year Re-Pricing for Preferably All Products, At Least 80%
November 30, 2020
- Japan to Set New Generic Target by March-End: Health Minister
November 30, 2020
- ICH to Stick to Urgent Topics with Significant Impact for Now amid COVID-19
November 30, 2020
- Sales Rep Promotions Up in All Channels in September: Intage
November 30, 2020
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…